Carvedilol Tablet, Film Coated
Product Images NDC 68071-4600

6 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68071-4600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

68071 4600 8

68071 4600 8
Label for Carvedilol 6.25 mg film-coated tablets by NuCare Pharmaceuticals, Inc. This prescription drug label indicates packaging of 180 tablets. Each oval-shaped white/off-white tablet is debossed with 'E' on one side and '02' on the other. The label includes NDC 68071-4600, manufacturer details, and storage instructions to keep at 68-77°F and out of reach of children.*
FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)
A survival analysis plot from the COPERNICUS study showing percent mortality over 21 months. The graph compares mortality rates between a placebo group and a carvedilol-treated group, illustrating lower mortality in the carvedilol group over time.*
FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)
A forest plot figure titled "Effects on Mortality for Subgroups in COPERNICUS" showing hazard ratios with 95% confidence intervals for various demographic and clinical subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use. The plot compares these subgroups against a vertical reference line at a hazard ratio of 1.0.*
FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)
A line graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)' showing mortality percentage over 24 months. It compares two groups, labeled 'Placebo' and 'Carvedilol', with mortality percentage on the Y-axis and months on the X-axis. The graph indicates lower mortality in the Carvedilol group compared to Placebo, with a P-value of 0.03.*
FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)
A forest plot figure titled 'Effects on Mortality for Subgroups in CAPRICORN' displaying hazard ratios for various patient subgroups. Group comparisons include age, gender, timing post-MI, prior beta-blocker use, clinical classifications, and comorbidities, with hazard ratios plotted along a scale from 0.4 to 1.3. Each subgroup has a point estimate and confidence intervals, illustrating relative mortality effects.*
FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical Structure (Carvedilol Str)
Chemical structure of carvedilol showing its molecular arrangement with an indole moiety, a methoxyphenyl group, and associated functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.